Home/Pipeline/AAV-GAD

AAV-GAD

Parkinson's Disease

Phase 2Active

Key Facts

Indication

Parkinson's Disease

Phase

Phase 2

Status

Active

Company

MeiraGTx

About MeiraGTx

MeiraGTx is a clinical-stage biotech focused on translating advanced genetic medicine into transformative therapies for diseases with high unmet need. Its strategy is built on a fully integrated platform combining novel vector engineering, precision gene control via its riboswitch technology, and in-house GMP manufacturing. Key achievements include a late-stage pipeline with Breakthrough Therapy designation for its xerostomia program and a major strategic collaboration with Eli Lilly in ophthalmology, positioning the company for significant value inflection.

View full company profile

Therapeutic Areas

Ophthalmology Neurodegeneration Metabolic Disorders Oncology

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active